ClinicalTrials.gg
CompletedNCT05500820Updated Aug 14, 2023

Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy Subjects

A Phase 1 interventional study of CIN-107 and Matching Placebo in Hypertension, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2020, 6 years 7 months ago, and no results have been posted to the registry.
  • Registered 2 years 7 months after the study started (first participant enrolled Dec 2019, registered Aug 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing baxdrostat in Hypertension — 2 open to participants now, 4 under way, 3 of them phase 3. baxdrostat · Hypertension.

Enrollment
11th of 18
56 · median 197
Started
2019
the only one that year
Phase 1
7 of 18
none open now
Registered
5th of 18
by date
Lead sponsor
16 of 18
AstraZeneca

Among the 18 studies testing baxdrostat in Hypertension, this one is the 11th largest by enrollment, is the only one that started in 2019, is one of 7 in phase 1, and was the 5th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

2 of the 18 studies testing baxdrostat in Hypertension are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About baxdrostat

baxdrostat: first FDA approval 2026 (BAXFENDY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing baxdrostat in Hypertension, or all of them as a file.
02

Study summary

This is a randomized, double-blind, study to assess the safety, tolerability, PK, and PD of multiple oral doses of CIN-107 when administered to healthy adult subjects.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • pharmacokinetics (PK), metabolism, baxdrostat
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy subjects between the ages of 18 and 55 years, inclusive, in good health based on medical and psychiatric history, physical examination, , orthostatic vital signs, and routine laboratory tests (blood chemistry, hematology, coagulation, and urinalysis).
  2. (BMI) between 18 and 30 kg/m2, inclusive.
  3. Nonsmokers who have not used nicotine-containing products for at least 6 months prior to the Screening Visit.

Exclusion criteria

Exclusion Criteria:

  1. Actively participating in an experimental therapy study; received experimental therapy with a small molecule within 30 days of Day 1, or 5 half-lives, whichever is longer; or received experimental therapy with a large molecule within 90 days of Day 1, or 5 half-lives, whichever is longer.
  2. A personal or family history of long syndrome, Torsades de Pointes, or other complex ventricular arrhythmias, or family history of sudden death.
  3. History of, or current, arrhythmias as judged by the Investigator, including ventricular tachycardia, ventricular fibrillation, or atrial fibrillation.
  4. Prolonged QTcF (>450 msec) based on the average of triplicate ECGs.
  5. Seated blood pressure higher than 150/90 mmHg or lower than 90/50 mmHg.
  6. Resting heart rate higher than 100 bpm or lower than 50 bpm , sinus node dysfunction, or clinically significant heart block.
  7. Temperature (T) greater than 37.6o C (99.68o F, measured orally), and respiration rate less than 12 and greater than 20 breaths/minute.
  8. Postural tachycardia (ie >30 bpm upon standing) or orthostatic hypotension (ie, a fall in systolic blood pressure (SBP) of ≥20 mm Hg or DBP of ≥ 10 mm Hg when a person assumes a standing position).
  9. Serum potassium > of the reference range (ULN) and serum sodium \< lower limit of normal of the reference range (LLN).
  10. (AST) and alanine aminotransferase (ALT) values > 1.2 ULN.
  11. Positive for (HIV) antibody, virus (HCV) antibody, or surface antigen (HBsAg).
  12. A known history of porphyria, myopathy, or an active liver disease.
  13. Positive drug or alcohol test result or a history of alcoholism or drug abuse within 2 years prior to the first dose of study drug as defined by the , 4th Edition: DSM-IV.
  14. Typical consumption of ≥14 alcoholic drinks weekly.
  15. Surgical procedures within 4 weeks of check-in or planned elective surgery during the study period.
  16. Currently undergoing treatment with weight loss medication or prior weight loss surgery (eg, gastric bypass surgery).
  17. Pregnant, breastfeeding, or planning to become pregnant during the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Cohort 1: 2.5 mg CIN-107

    Subjects on a low salt diet

    Drug: CIN-107

  • Experimental
    Cohort 2: 5.0 mg CIN-107

    Subjects on a low salt diet

    Drug: CIN-107

  • Experimental
    Cohort 3: 1.5 mg CIN-107

    Subjects on a normal salt diet

    Drug: CIN-107

  • Experimental
    Cohort 4: 2.5 mg CIN-107

    Subjects on a normal salt diet

    Drug: CIN-107

  • Experimental
    Cohort 5: 0.5 mg CIN-107

    Subjects on a normal salt diet

    Drug: CIN-107

  • Placebo comparator
    Cohort 1: 2.5 mg matching placebo

    Subjects on a low salt diet

    Drug: Matching Placebo

  • Placebo comparator
    Cohort 2: 5.0 mg matching placebo

    Subjects on a low salt diet

    Drug: Matching Placebo

  • Placebo comparator
    Cohort 3: 1.5 mg matching placebo

    Subjects on a normal salt diet

    Drug: Matching Placebo

  • Placebo comparator
    Cohort 4: 2.5 mg matching placebo

    Subjects on a normal salt diet

    Drug: Matching Placebo

  • Placebo comparator
    Cohort 5: 0.5 mg matching placebo

    Subjects on a normal salt diet

    Drug: Matching Placebo

Interventions

  • A repeat oral dose of CIN-107 once daily for 10 days.

    Also known as: baxdrostat

  • DrugMatching Placebo

    A repeat oral dose of matching placebo once daily for 10 days.

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax)

    This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data and following the first and last doses of CIN-107, as the data permit.

    Time frame: up to Day 15

  2. Time to maximum plasma concentration (Tmax)

    This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data and following the first and last doses of CIN-107, as the data permit.

    Time frame: up to Day 15

  3. Area under the curve from time 0 to the time of last quantifiable plasma concentration (AUC[0-last])

    This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data following the final dose of CIN-107, as the data permit.

    Time frame: up to Day 15

  4. Area under the curve from time 0 to infinity

    This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data following the final dose of CIN-107, as the data permit.

    Time frame: up to Day 15

  5. Area under the curve over a dosing interval (tau)

    This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data following the final dose of CIN-107, as the data permit.

    Time frame: up to Day 15

  6. Area under the plasma concentration-time curve (AUC) from time 0 to 24 hours

    This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data and following the first dose of CIN-107, as the data permit.

    Time frame: up to Day 2

  7. Percent of AUC extrapolated

    This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data following the final dose of CIN-107, as the data permit.

    Time frame: up to Day 15

  8. Terminal phase elimination half-life

    This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data following the final dose of CIN-107, as the data permit.

    Time frame: up to Day 15

  9. Apparent plasma clearance

    This PK parameter will be determined for CIN-107 using plasma concentration data.

    Time frame: up to Day 15

  10. Apparent volume of distribution

    This PK parameter will be determined for CIN-107 using plasma concentration data.

    Time frame: Up to Day 15

  11. The cumulative amount of CIN-107 and CIN-107-M excreted in the urine (Ae)

    This PK parameter will be calculated using the urine concentrations of CIN-107 and its primary metabolite (CIN-107-M)

    Time frame: up to Day 15

  12. Renal clearance (CLR Calculated as Ae/AUC) of CIN-107 and CIN-107-M

    This PK parameter will be calculated using the urine concentrations of CIN-107 and its primary metabolite (CIN-107-M)

    Time frame: up to Day 15

  13. Fraction of the dose excreted renally (fe)

    This PK parameter will be calculated using the urine concentrations of CIN-107

    Time frame: up to Day 15

  14. Number of patients experiencing adverse events (AEs)

    Time frame: up to Day 15

  15. Number of patients experiencing adverse drug reactions

    Time frame: up to Day 15

  16. Number of patients experiencing serious adverse events (SAEs)

    Time frame: up to Day 15

  17. Plasma concentration of aldosterone

    Time frame: up to Day 15

  18. Plasma renin activity

    Time frame: up to Day 15

  19. Plasma concentration of cortisol (free and total)

    Time frame: up to Day 15

  20. Plasma concentration of ACTH (Adrenocorticotropic hormone)

    Time frame: up to Day 15

07

Study locations

1 site
  • Medpace Clinical Pharmacology Unit
    Cincinnati, Ohio 45227, United States
08

References and documents

Publications

  • Freeman MW, Bond M, Murphy B, Hui J, Isaacsohn J. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers. Hypertens Res. 2023 Jan;46(1):108-118. doi: 10.1038/s41440-022-01070-4. Epub 2022 Oct 20. PubMed 36266539 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Apr 2020, 3 months.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 3 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2022
First posted
Aug 15, 2022
StartActual
Dec 19, 2019
Primary completionActual
Apr 3, 2020
CompletionActual
Apr 3, 2020
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05500820
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 15, 2022
Start date
Dec 19, 2019
Primary completion
Apr 3, 2020
Completion
Apr 3, 2020
Last update
Aug 14, 2023

Study contacts

Leela Vrishabhendra, MD
principal investigator · Medpace Clinical Pharmacology Unit

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baxdrostat

Start the discussion